StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting.
安大略省多倫多-(Newsfile Corp.-2023年6月5日)-StageZero生命科學有限公司(多倫多證券交易所股票代碼：SZLS)(以下簡稱“StageZero”或“公司”)今天宣佈，將於2023年6月7日(星期三)召開一次電話會議，作為股東特別大會和年度股東大會的一部分，以便所有股東都能關注會議的進程。
Annual General and Special Meeting Conference Call
年度大會和特別會議電話會議
Event Date: Wednesday June 7, 2023
Time: 2:00pm ET
Webcast Link:
活動日期時間：2023年6月7日星期三
時間：美國東部時間下午2：00
網路直播鏈接：
Conference Call Numbers
電話會議號碼
Canada/USA TF: 1-800-319-4610
Toronto Toll: +1-416-915-3239
International Toll: +1-604-638-5340
加拿大/美國電話：1-800-319-4610
多倫多通行費：+1-416-915-3239
國際通行費：+1-604-638-5340
About StageZero Life Sciences, Ltd.
StageZero生命科學有限公司簡介
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT).
StageZero生命科學有限公司是一家垂直整合的醫療保健公司，致力於通過下一代診斷和獨特的遠端醫療計劃來改善癌症和其他慢性病的早期檢測和管理，該計劃提供臨床幹預措施，幫助患者降低發展為晚期疾病(AVRT)的風險。
The Company's next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
該公司的下一代測試亞裡士多德是有史以來第一個同時從單一血液樣本中篩查多種癌症的信使核糖核酸多癌症小組，對每種癌症都具有高度的敏感性和特異性。亞裡士多德使用信使核糖核酸技術來識別多種癌症類型的分子特徵，並建立在該公司的專利技術平臺哨兵原理的基礎上。這項潛在的技術已經在9000多名患者中得到驗證，並在北美被10萬多名患者使用。
Aristotle is processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company provides patients with multiple clinical programs, for risk management and treatment, through its subsidiary Care Oncology.
亞裡士多德在該公司的臨床實驗室StageZero生命科學公司進行處理，StageZero生命科學公司是位於弗吉尼亞州里士滿的CAP認證和CLIA認證的高複雜性參考實驗室。此外，該公司通過其子公司Care Oncology為患者提供多種臨床專案，用於風險管理和治療。
StageZero Life Sciences, Ltd. trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
StageZero生命科學有限公司在多倫多證券交易所的交易代碼為SZLS，在OTCQB的交易代碼為SZLSF。
For further information please contact:
欲瞭解更多資訊，請聯繫：
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
投資者關係
麗貝卡·格雷科
1-855-420-7140分機1838年
郵箱：rgreco@stagezerols.com
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。